bearish
Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO
1k Views07 Dec 2018 15:32
Ascentage Pharma, a China-based biotech company, filed an application to list on the Hong Kong Stock Exchange. In this insight, we will cover the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
- Ascentage Pharma (亚盛医药) IPO: Some Issues with Banker Forecasts01 Oct 2019
- Ascentage Pharma (亚盛医药) IPO: Thoughts on Valuation24 Jun 2019
- Ascentage Pharma (亚盛医药) IPO: Updates and Thoughts on HQP1351 (3rd Gen Bcr-Abl TKI)19 Jun 2019
- Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO07 Dec 2018
- Wuxi Apptec (药明康德) IPO: Pricing Update Before Book Close06 Dec 2018
- WuXi Apptec (药明康德) IPO:Upside at Middle and Low End28 Nov 2018
x